Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

Core Insights - Tevogen Bio Holdings Inc. has signed a non-exclusive, non-binding Letter of Intent to evaluate a potential transaction with Apozeal Pharmaceutical Inc., which focuses on developing and manufacturing cost-effective medicines [1][2] Group 1: Proposed Transaction - The potential acquisition of Apozeal is seen as a strategic move to advance Tevogen Generics, aimed at supporting domestic pharmaceutical manufacturing and enhancing affordability and supply chain resilience in the U.S. [2] - Apozeal offers FDA-approved Abbreviated New Drug Application (ANDA) assets and a growing development pipeline, which could provide a foundation for Tevogen's generics business [2][9] - The transaction is subject to due diligence, negotiation, execution of definitive documentation, required approvals, and customary closing conditions [2] Group 2: Company Overview - Tevogen is a healthcare enterprise focused on affordability, efficiency, and scientific rigor, leveraging AI and precision T cell therapy platforms [4] - The company has completed a proof-of-concept clinical trial for its genetically unmodified allogeneic T cells, with a pipeline that includes programs in virology, oncology, and neurology [5] - Tevogen.AI aims to transform drug development by accelerating target detection and optimizing clinical trial design through predictive technologies [6] Group 3: Future Initiatives - Tevogen is exploring additional strategic initiatives, including domestic generics, biosimilars, medical devices, and innovative insurance solutions, to broaden patient access and advance sustainable innovation [7]